CONSTITUTIVE EXPRESSION OF CHIMERIC NEO-REV RESPONSE ELEMENT TRANSCRIPTS SUPPRESSES HIV-1 REPLICATION IN HUMAN CD4(+) T-LYMPHOCYTES

被引:29
作者
BEVEC, D
VOLCPLATZER, B
ZIMMERMANN, K
DOBROVNIK, M
HAUBER, J
VERES, G
BOHNLEIN, E
机构
[1] PROGENESYS,PALO ALTO,CA 94303
[2] SANDOZ GMBH,RES INST,ART DEPT,VIENNA,AUSTRIA
[3] UNIV VIENNA,INST VIROL,LSGT,VIRCC,A-1095 VIENNA,AUSTRIA
关键词
D O I
10.1089/hum.1994.5.2-193
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
We have previously reported that chimeric neomycin phosphotransferase (neo)-Rev response element (RRE) transcripts suppress the function of the human immunodeficiency virus type 1 (HIV-1) Rev trans-activator protein in HeLa cells. In an extension of these experiments, human CD4(+) CEM cells (G418-resistant cell populations and clonal isolates) stably expressing chimeric neo-RRE genes (2, 3, or 6 RRE copies) were generated using retroviral-mediated gene transfer. The transduced CEM clones were infected with the HIV-1 HTLV(IIIb) isolate and the following three phenotypes were observed: (i) the transduced CEM cells were readily infected with HIV-1 indistinguishable from the control CEM cells; (ii) the appearance of HIV-1 replication markers was significantly delayed; (iii) no signs of HIV-1 replication were detectable although proviral HIV-1 DNA sequences could be detected in these cells. Furthermore, HIV antigen expression was limited in neo-resistant CEM cell populations inoculated with the HIV-1 HTLV(IIIb) isolate. Only 10% of the CEM-pX17-3xRRE cells and 20% of the CEM-pX17-2xRRE cells displayed HIV-1 antigens 43 days after challenge and had retained CD4 surface expression on 47% and 64% of the cells, respectively. In sharp contrast, 80% of the CEM-pX17 or the CEM-pX17-6xRRE cells expressed HIV-1 antigens but no CD4 antigens were detectable in these cultures. These results clearly indicate that RRE decoys could be developed into an effective somatic gene therapy approach against HIV-1 induced acquired immunodeficiency syndrome (AIDS).
引用
收藏
页码:193 / 201
页数:9
相关论文
共 27 条
[1]   STRUCTURE-FUNCTION ANALYSES OF THE HTLV-I REX AND HIV-1 REV RNA RESPONSE ELEMENTS - INSIGHTS INTO THE MECHANISM OF REX AND REV ACTION [J].
AHMED, YF ;
HANLY, SM ;
MALIM, MH ;
CULLEN, BR ;
GREENE, WC .
GENES & DEVELOPMENT, 1990, 4 (06) :1014-1022
[2]   COMPARISON OF TRANSDOMINANT INHIBITORY MUTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 GENES EXPRESSED BY RETROVIRAL VECTORS IN HUMAN T-LYMPHOCYTES [J].
BAHNER, I ;
ZHOU, C ;
YU, XJ ;
HAO, QL ;
GUATELLI, JC ;
KOHN, DB .
JOURNAL OF VIROLOGY, 1993, 67 (06) :3199-3207
[3]   GENE-THERAPY - INTRACELLULAR IMMUNIZATION [J].
BALTIMORE, D .
NATURE, 1988, 335 (6189) :395-396
[4]   NUCLEOTIDE-SEQUENCE AND EXACT LOCALIZATION OF THE NEOMYCIN PHOSPHOTRANSFERASE GENE FROM TRANSPOSON TN5 [J].
BECK, E ;
LUDWIG, G ;
AUERSWALD, EA ;
REISS, B ;
SCHALLER, H .
GENE, 1982, 19 (03) :327-336
[5]   INHIBITION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION IN HUMAN T-CELLS BY RETROVIRAL-MEDIATED GENE-TRANSFER OF A DOMINANT-NEGATIVE REV TRANSACTIVATOR [J].
BEVEC, D ;
DOBROVNIK, M ;
HAUBER, J ;
BOHNLEIN, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (20) :9870-9874
[6]   A UNIVERSAL RETROVIRAL VECTOR FOR EFFICIENT CONSTITUTIVE EXPRESSION OF EXOGENOUS GENES [J].
BOULTER, CA ;
WAGNER, EF .
NUCLEIC ACIDS RESEARCH, 1987, 15 (17) :7194-7194
[7]   ISOLATION OF BIOLOGICALLY-ACTIVE RIBONUCLEIC-ACID FROM SOURCES ENRICHED IN RIBONUCLEASE [J].
CHIRGWIN, JM ;
PRZYBYLA, AE ;
MACDONALD, RJ ;
RUTTER, WJ .
BIOCHEMISTRY, 1979, 18 (24) :5294-5299
[8]   INHIBITION OF REV-MEDIATED HIV-1 EXPRESSION BY AN RNA-BINDING PROTEIN ENCODED BY THE INTERFERON-INDUCIBLE-9-27 GENE [J].
CONSTANTOULAKIS, P ;
CAMPBELL, M ;
FELBER, BK ;
NASIOULAS, G ;
AFONINA, E ;
PAVLAKIS, GN .
SCIENCE, 1993, 259 (5099) :1314-1318
[9]   REGULATORY PATHWAYS GOVERNING HIV-1 REPLICATION [J].
CULLEN, BR ;
GREENE, WC .
CELL, 1989, 58 (03) :423-426
[10]   HUMAN-IMMUNODEFICIENCY-VIRUS AS A PROTOTYPIC COMPLEX RETROVIRUS [J].
CULLEN, BR .
JOURNAL OF VIROLOGY, 1991, 65 (03) :1053-1056